On September 10, 2020 Varian (NYSE: VAR) reported the Goshen Center for Cancer Care in Goshen, Ind., treated its first patient with Ethos therapy, marking the first availability of this advanced cancer treatment in the state of Indiana (Press release, Varian Medical Systems, SEP 10, 2020, View Source [SID1234564937]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Ethos therapy system combines an image-guided radiation therapy (IGRT) powerhouse with artificial intelligence (AI) adaptive capabilities in one system, creating workflow efficiencies that benefit both patient and clinician. This new solution is designed to deliver an entire adaptive treatment in a typical 15-minute timeslot, from patient setup through treatment delivery, making it ideal for a busy center. Incorporating multi-modality images, the Ethos adaptive therapy provides the ability to personalize the patient’s treatment based on their anatomy and position at the time of treatment. The goal is to better target the tumor, enable more customized margins, and potentially improve overall outcomes with a reduction in dose to healthy tissue.

"In the 25 years I have been in the field of radiation oncology, adaptive radiotherapy is the most revolutionary technology I have seen," said John P. Lowden, MS, DABR, Medical Physicist, Goshen Center for Cancer Care. "Ethos allows community cancer centers like Goshen Center for Cancer Care to provide adaptive daily treatments in an affordable and efficient package that keeps patient-centered design at its core."

Ethos therapy has the potential to ensure that advanced treatment approaches are available to any patient regardless of their proximity to major metropolitan cities or academic medical centers. An AI-assisted adaptive therapy system with an intelligent optimization engine and guided workflow, such as Ethos, can move adaptive therapy from a specialty offering by large centers into the mainstream of care. Ethos also offers the flexibility to choose adaptive or non-adaptive therapy to maximize operational efficiencies.

"Every patient deserves personalized cancer care," said Chris Toth, president of Varian Oncology Systems. "Varian is honored to be working with Goshen Health as one of the first hospitals nationally to bring Ethos adaptive treatments to patients and help all of us move closer to creating a world without fear of cancer."

"Ethos adaptive planning is truly remarkable technology," said Chelsea Poscharsky, RTT, Goshen Center for Cancer Care. "Because Ethos enables the creation of on-table adaptive plans, patients who would normally spend an entire day with us to get their anatomy correct prior to treatment are able to be treated within a 15-20-minute time slot. All without sacrificing treatment effectiveness or increasing patient side effects."

On September 10, 2020 Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, reported that the company will participate in the 18th Annual Morgan Stanley Global Healthcare Conference (Press release, Avid Bioservices, SEP 10, 2020, View Source [SID1234564936]). The conference, which will take place September 14-18, 2020, is being conducted with a virtual format.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the company’s participation are as follows:

18th Annual Morgan Stanley Global Healthcare Conference
Details: Avid management will participate in a fireside chat and 1-on-1 meetings
Conference Date: September 14-18, 2020
Fireside Chat Time/Date: 4:15 p.m. Eastern on Thursday, September 17, 2020
Format: Virtual Conference
A webcast of the fireside chat will be made available. To listen to the live webcast, or access the archived webcast, please visit: View Source

On September 10, 2020 Boehringer Ingelheim reported the advancement of the bi-specific and tetravalent therapeutic antibody, BI 905711, to its first-in-human clinical trial for patients with advanced gastrointestinal (GI) cancers (Press release, Boehringer Ingelheim, SEP 10, 2020, View Source [SID1234564934]). The first-in-class BI 905711 antibody is designed to recognize both the pro-apoptotic tumor necrosis factor (TNF)-related apoptosis-inducing ligand receptor 2 (TRAILR2) and the tumor cell anchor cadherin 17 (CDH17) to activate the self-destruction (apoptosis) pathway in co-expressing tumor cells found mostly in the GI tract. For patients suffering from these types of cancers, the advancement of the Phase 1 trial marks an important milestone in the continuing development of more tolerable innovative therapies to address diseases with high unmet need.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are proud to advance BI 905711 into Phase 1 clinical trials as we continue to grow our oncology pipeline to transform patients’ lives. This bispecific platform has the potential to target complex mechanisms that may not be accessible with traditional antibody formats," said Norbert Kraut, Ph.D., Head of Global Cancer Research at Boehringer Ingelheim.

Gastrointestinal cancers are a leading cause of cancer-related deaths throughout the world. Of gastrointestinal cancers, colorectal cancer, a focus of this Phase 1 trial, is the third most common cancer with more than 1.8 million cases and the second most deadly cancer with more than 880,000 deaths globally in 2018 (Globocan 2018).¬ To date there have been few innovative treatment options available for patients diagnosed with GI malignancies, making chemotherapy, despite its known severe side effects, the backbone of treatment. A proven targeted therapeutic option that does not require chemotherapy efficacy support could provide patients with an alternative, innovative and potentially non-toxic treatment option.

James Harding, M.D., Principal Investigator, Department of Early Drug Development and Gastrointestinal Oncology Service at Memorial Sloan Kettering Cancer Center, New York, USA, said, "Targeting TRAILR2/CDH17 co-expressing cancer cells has exhibited preclinical antitumor activity. We look forward to evaluating this molecule with Boehringer Ingelheim in the ongoing Phase 1 study."

Patients with tumors of the gastrointestinal tract are underserved by recent innovations in cancer therapy and are in critical need of new treatment options. Boehringer Ingelheim is committed to addressing the unmet need in these patients’ lives and continues to develop innovative drug candidates, such as BI 905711, providing potentially powerful and previously untested approaches to cancer treatment.

Boehringer Ingelheim Oncology is taking cancer on by leading the science with cancer cell directed agents, immuno-oncology therapies, and their combinations to address unmet needs in lung and gastrointestinal cancers. The company invests significantly in early stage research to identify unexplored and undrugged pathways of cancer. In 2019, Boehringer Ingelheim advanced six molecules to first-in-human studies, including two further first-in-class compounds targeting the Wnt/β-catenin pathway (BI 905681) and KRAS-driven cancers (BI 1701963), demonstrating the company’s long term commitment to leading science, improving clinical practice, and ultimately transforming the lives of patients – helping them to win the fight against cancer.

On September 10, 2020 Cancer Genetics, Inc. (the "Company") (Nasdaq: CGIX), a leader in drug discovery and preclinical oncology and immuno-oncology services, reported it will present at the 22nd Annual Rodman & Renshaw Global Investment Conference sponsored by H.C. Wainwright & Co., LLC. The conference is being held virtually from September 14-16, 2020 (Press release, Cancer Genetics, SEP 10, 2020, View Source [SID1234564933]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Event: 22nd Annual Rodman & Renshaw Global Investment Conference
Date: September 16, 2020
Time: 11:30am ET
Conference Details: www.rodmanevents.com

Cancer Genetics’ management team will provide an overview of the Company’s business and scientific advancements during the live presentation and will be available to participate in one-on-one virtual meetings with investors who are registered to attend the conference. Management will also be available for virtual investor meetings outside the conference.

If you are an institutional investor and would like to attend the Company’s presentation, please click on the following link (www.rodmanevents.com) to register for the Rodman & Renshaw conference. Once your registration is confirmed, you will be prompted to log into the conference website and also be able to request a one-on-one meeting with the Company.

For further information about attending the Company’s presentation or to book an individual appointment with Cancer Genetics’ management, please contact Jennifer K. Zimmons, Ph.D., at +1 917.214.3514 or [email protected].

To see the full list of upcoming events where the Company intends to present or participate, please visit Cancer Genetics’ web site under Events & Presentations.

On September 10, 2020 Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, reported that Brian M. Culley, Chief Executive Officer will be presenting at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 at 3:00 pm Eastern Time / 12:00 pm Pacific Time (Press release, Lineage Cell Therapeutics, SEP 10, 2020, View Source [SID1234564932]). Mr. Culley and Brandi L. Roberts, Chief Financial Officer, will also be presenting at the 2020 Cantor Virtual Global Healthcare Conference on September 17, 2020 at 12:00 pm Eastern Time / 9:00 am Pacific Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested investors can access both live presentations on the Events and Presentations section of Lineage’s website and archived presentations will be available for 30 days. Additional videos are available on the Media page of the Lineage website, located at www.lineagecell.com/media/.